Skip to content

Investigating the use of a new fluorescent compound to identify pre cancerous and cancerous lesions in the bowel

Investigating the use of a fluorescent lectin to identify dysplasia and cancer during endoscopy and surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN90128107
Enrollment
50
Registered
2017-04-07
Start date
2016-07-01
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer Cancer Colorectal cancer

Interventions

For patients having endoscopy, they will initially have their colonoscopy with white light as is standard practice. The fluorescent lectin is applied to any lesions identified with white light and an

Sponsors

University of Oxford
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male or female, aged 18 years or over 3. Patients undergoing endoscopic procedures including colonoscopy and flexible sigmoidoscopy as well as transanal endoscopic microsurgery (TEMS), including robotic assisted TEMS 4. In the investigator’s opinion, is able and willing to comply with all study requirements;Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male or female, aged 18 years or over 3. Patients undergoing endoscopic procedures including colonoscopy and flexible sigmoidoscopy as well as transanal endoscopic microsurgery (TEMS), including robotic assisted TEMS 4. In the investigator’s opinion, is able and willing to comply with all study requirements

Exclusion criteria

Exclusion criteria: 1. Patient who is unable or unwilling to give informed consent 2. Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. If there is an uncertainly regarding whether a woman could be pregnant, then they will be excluded from the study. 3. Patients with known egg allergies, ovalbumin allergy and soya allergies;Exclusion criteria: 1. Patient who is unable or unwilling to give informed consent 2. Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. If there is an uncertainly regarding whether a woman could be pregnant, then they will be excluded from the study. 3. Patients with known egg allergies, ovalbumin allergy and soya allergies

Design outcomes

Primary

MeasureTime frame
1. Signal to background ratio after application of lectin is measured using the fluorescence ratio of WFA binding to normal versus dysplastic/early cancer tissue during endoscopic or surgical procedure 2. Detection rate of dysplastic and cancerous lesions compared to white light alone is measured as the number of lesions identified during endoscopic or surgical procedure and calculating the sensitivity and specificity ;1. Signal to background ratio after application of lectin is measured using the fluorescence ratio of WFA binding to normal versus dysplastic/early cancer tissue during endoscopic or surgical procedure 2. Detection rate of dysplastic and cancerous lesions compared to white light alone is measured as the number of lesions identified during endoscopic or surgical procedure and calculating the sensitivity and specificity

Secondary

MeasureTime frame
No secondary outcome measures;No secondary outcome measures

Countries

United Kingdom

Contacts

Public ContactThomas;Thomas Barnes;Barnes

;

;;

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026